$180 million UroCor deal advances Dianon's strategy
This article was originally published in Clinica
Executive Summary
Dianon Systems, a US cancer diagnostic pathology company, has signed a definitive agreement to acquire UroCor, a urological diagnosis company, in a share transaction that values UroCor at $180 million. The deal creates a company with a leading share in the urology sector of the cancer diagnostics market in the US. Dianon had tried and failed to acquire the company three years ago.